VCELVericel Corporation

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+25.0% YoY

Gross Profit

$35M68.9% margin

Operating Income

-$5M-10.7% margin

Net Income

-$4M-7.5% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-21.1%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$357M

Total Liabilities

$123M

Stockholders' Equity

$234M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$41M	+25.0%
Gross Profit	$35M	$27M	+33.3%
Operating Income	-$5M	-$8M	+33.2%
Net Income	-$4M	-$7M	+48.5%

Revenue Segments

MACI Implants And Kits

$40M100%

VCEL Q1 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena